Lead Product(s) : Perillyl Alcohol
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : NeOnc Technologies
Deal Size : Undisclosed
Deal Type : Partnership
Anova Partners with NeOnc Technologies to Bring NEO100 to Patients With IDH1 Mutated Gliomas
Details : As part of the partnership, Anova will support patient identification and access to NEO100 clinical trials, and when clinical trials are not an option for patients with IDH1 mutated Glioma, early access for compassionate use will be supported.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 29, 2021
Lead Product(s) : Perillyl Alcohol
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : NeOnc Technologies
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Perillyl Alcohol
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2016
Lead Product(s) : Perillyl Alcohol
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable